Brief: Reata Pharmaceuticals Inc Announces Q3 2021 Financial Results, Provides An Update On Clinical Development Programs
08/11/2021 11:44
Nov 8 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2021
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT
PROGRAMS
* Q3 NON-GAAP LOSS PER SHARE $1.27
* Q3 GAAP LOSS PER SHARE $1.97
* AT SEPTEMBER 30, 2021, WE HAD CASH AND CASH EQUIVALENTS OF
$713.2 MILLION
* REAFFIRM CURRENT CASH RUNWAY TO LAST THROUGH MID-2024
* Q3 EARNINGS PER SHARE VIEW $-2.17 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw9DCj2Sa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer